In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Moderna raises $110mm in second financing round

Executive Summary

Messenger RNA company Moderna Therapeutics Inc. raised $110mm through what appears to be the company's Series B round. The financing came from 39 undisclosed private investors, a large syndicate that EBI assumes includes the company's only published investor--Flagship Ventures. Moderna has now raked in $415mm in cash in just one year: a $40mm first round in December 2012; $240mm up front from AstraZeneca as part of a 40-project licensing deal signed in March; a $25mm grant from the Defense Advanced Research Projects Agency in October; and the current $110mm financing.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies